baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Viatris Inc./ US92556V1061 /

10/06/2024 07:57:22	Chg. +0.1640	Volume	Bid12:00:28	Ask12:00:28	Market Capitalization	Dividend Y.	P/E Ratio
9.7420EUR	+1.71%	- Turnover: -	9.6300Bid Size: 730	9.7740Ask Size: 730	11.54 bill.EUR	-	-

GlobeNewswire 03/06 Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

GlobeNewswire 10/05 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire 06/05 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

GlobeNewswire 03/05 Ocuphire Pharma to Present at the Aegis Virtual Conference

GlobeNewswire 01/05 NeurologyLive® and CMSC Announce the 3rd Annual Class of Inductees

GlobeNewswire 22/04 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting

GlobeNewswire 11/04 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...

GlobeNewswire 01/04 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...

GlobeNewswire 20/03 Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...

GlobeNewswire 08/03 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...

TeleTrader 28/02 US closes lower after GDP data, ahead of earnings

GlobeNewswire 28/02 Idorsia and Viatris enter into a significant global research and development collaboration

GlobeNewswire 23/02 Ocuphire Pharma to Present in the BIO CEO & Investor Conference

GlobeNewswire 15/02 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 14/02 ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...

GlobeNewswire 14/02 Ocuphire Pharma Strengthens Leadership Team with Key Appointments

GlobeNewswire 05/02 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...

GlobeNewswire 02/02 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire 24/01 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 04/01 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...

GlobeNewswire 02/01 VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...

GlobeNewswire 30/11/2023 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

GlobeNewswire 30/11/2023 Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...

GlobeNewswire 27/11/2023 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 27/11/2023 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Viatris Inc./ US92556V1061 /

If you wish to receive reply to your feedback, please provide your email address.